8-K: FOXO Technologies Amends Preferred Stock Terms, Boosts Authorized Shares

FOXO Technologies Inc. has amended its Series B and C Preferred Stock conversion terms, significantly increased authorized common and preferred shares, and re-elected its board of directors.

Summary

• Amended Series B and C Preferred Stock conversion price to be the higher of $0.0001 or 90% of the 5-day average VWAP, and removed the mandatory conversion provision.
• Exempted dividends paid to Series E Cumulative Redeemable Secured Preferred Stock holders from certain restrictions on dividend payments and share redemptions.
• Increased authorized Class A Common Stock from 2,500,000,000 shares to 10,000,000,000 shares.
• Increased authorized Preferred Stock from 10,000,000 shares to 20,000,000 shares.
• Re-elected five directors: Seamus Lagan, Trevor Langley, Francis Colt deWolf III, Bret Barnes, and Mark White.
• Ratified the appointment of Kreit & Chiu CPA LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• These actions were approved by Rennova Health, Inc., the majority stockholder (controlled by the Company's CEO), which held approximately 98.6% of the Company's voting rights.

Sentiment

Score: 3

Explanation: The filing indicates significant potential for future shareholder dilution due to the large increase in authorized shares and the dilutive nature of the preferred stock conversion terms. While board continuity is a minor positive, the overall impact on common shareholders is likely negative due to the increased supply of shares and the strong control by a single majority shareholder.

Positives

• Re-election of the current Board of Directors provides continuity in leadership.
• Ratification of the independent auditor for fiscal year 2025 ensures ongoing financial oversight.

Negatives

• Significant increase in authorized common stock (4x) and preferred stock (2x) could lead to substantial dilution for existing common stockholders if these shares are issued.
• Removal of the mandatory conversion provision for Series B and C Preferred Stock gives holders more flexibility but removes a potential catalyst for common stock conversion.
• The conversion price for Series B and C Preferred Stock is set at the higher of $0.0001 or 90% of VWAP, which is highly dilutive if the stock price is low.
• The majority stockholder, Rennova Health, Inc. (controlled by the CEO), holding 98.6% of voting rights, effectively controls all corporate actions, limiting influence from other shareholders.

Risks

• Dilution Risk: The substantial increase in authorized shares of both Class A Common Stock (from 2.5 billion to 10 billion) and Preferred Stock (from 10 million to 20 million) creates a significant risk of future dilution for current shareholders if these shares are issued.
• Conversion Price Risk: The conversion price for Series B and C Preferred Stock is tied to 90% of the 5-day average VWAP, which means conversions at lower stock prices would result in more common shares being issued, exacerbating dilution.
• Corporate Governance Risk: The majority stockholder (Rennova Health, Inc., controlled by the CEO) holds 98.6% of voting rights, concentrating control and potentially limiting the influence of minority shareholders on corporate decisions.
• Preferred Stock Seniority: Series B and C Preferred Stock rank junior to Series A Preferred Stock and other Senior Securities in terms of dividends and liquidation, indicating a layered capital structure.

Future Outlook

The Board of Directors has the sole discretion to determine the effective date of the authorized share increase anytime before April 30, 2026, without further stockholder approval. The items approved by the majority stockholder will become effective 20 days after the mailing of the definitive Information Statement on Schedule 14C.

Management Comments

• The Chief Executive Officer, the president or any vice-president, and the secretary or any assistant secretary, of the Corporation are authorized and directed to prepare and file the Certificate of Designation of Preferences, Rights and Limitations in accordance with the resolution and Delaware law.

Industry Context

This filing primarily addresses internal corporate governance and capital structure adjustments, which are common actions for companies, particularly those that may be seeking flexibility for future financing or strategic transactions. The significant increase in authorized shares suggests a potential need for future capital raises or M&A activities, aligning with broader trends of companies adjusting their capital structures to support growth or operational needs.

Comparison to Industry Standards

• The increase in authorized shares is a common corporate action, but a quadrupling of common stock and doubling of preferred stock authorization is a substantial increase, potentially signaling significant future capital needs or strategic shifts. This level of increase could be seen as aggressive compared to typical incremental adjustments.
• The conversion price mechanism for preferred stock (higher of $0.0001 or 90% of 5-day VWAP) is a common anti-dilution protection for preferred holders, but the $0.0001 floor is extremely low, suggesting the company's stock price may be very low, making the 90% VWAP the more likely effective conversion price, which is standard for such instruments.
• The concentration of voting power (98.6% by one majority stockholder controlled by the CEO) is atypical for widely held public companies and raises corporate governance concerns regarding minority shareholder influence, though it is not uncommon in companies with a strong controlling interest.

Management Changes

Corporate Governance

Related Party Transactions

• Rennova Health, Inc., which is controlled by FOXO Technologies Inc.'s CEO, Seamus Lagan, acted as the Majority Stockholder, approving all actions by written consent.

Stakeholder Impact

• Shareholders (Common Stock): Face significant potential dilution due to the quadrupling of authorized common shares and doubling of preferred shares. The preferred stock conversion terms (90% VWAP) also contribute to potential dilution. The concentration of voting power with the majority stockholder limits their influence.
• Preferred Stockholders (Series B & C): Benefit from revised conversion terms that remove mandatory conversion, offering more flexibility, and a conversion price tied to VWAP, providing a discount.
• Preferred Stockholders (Series E): Benefit from the exemption of their dividends from certain payment restrictions, potentially enhancing the security of their dividend payments.
• Management/Board: The re-election of the board members ensures continuity in leadership and strategic direction. The CEO, through Rennova Health, Inc., maintains strong control over the company's direction.

Next Steps

• The Company will mail the definitive Information Statement on Schedule 14C to its stockholders of record.
• The approved items will become effective 20 days after the mailing of the definitive Information Statement.
• The Board of Directors will determine the effective date for the authorized share increase anytime before April 30, 2026.

Key Dates

Recommendation

The substantial increase in authorized common and preferred shares, coupled with the dilutive conversion terms of the preferred stock and the removal of mandatory conversion, creates significant downside risk for existing common shareholders through potential future dilution. The overwhelming control by a single majority shareholder (controlled by the CEO) further limits minority shareholder influence. These factors suggest a negative outlook for common stock value, warranting a "sell" recommendation for investors.

Keywords

FOXO Technologies, Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Conversion Price, Authorized Shares, Stock Dilution, Corporate Governance, SEC Filing, 8-K, Rennova Health, Board of Directors, Shareholder Vote, Capital Structure